目的 探討金烏骨通膠囊聯(lián)合依降鈣素注射液治療骨質(zhì)疏松癥的臨床療效。方法 選取2017年2月—2017年8月在肥城礦業(yè)中心醫(yī)院進(jìn)行治療的骨質(zhì)疏松癥患者78例，隨機(jī)分為對照組（39例）和治療組（39例）。對照組患者肌肉注射依降鈣素注射液，1 mL/次，1次/周；治療組在對照組基礎(chǔ)上口服金烏骨通膠囊，1.5 g/次，3次/d。兩組患者均治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者VAS和ODI評分及骨代謝指標(biāo)情況。結(jié)果 治療后，對照組和治療組臨床總有效率分別為82.05%、97.44%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組視覺模擬評分法（VAS）和功能障礙指數(shù)（ODI）評分均顯著降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且VAS和ODI評分明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清硬骨素（SOST）、骨鈣素（BGP）水平均升高，β膠原特殊序列（β-CTX）、抗酒石酸酸性磷酸酶（TRACP）和N端骨鈣素（N-MID）水平均降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述骨代謝指標(biāo)顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 金烏骨通膠囊聯(lián)合依降鈣素注射液治療骨質(zhì)疏松癥可有效改善患者臨床癥狀和血清骨代謝指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Jinwu Gutong Capsules combined with calcitonin in treatment of osteoporosis. Methods Patients (78 cases) with osteoporosis in Feicheng Mining Center Hospital from February 2017 to August 2017 were randomly divided into control (39 cases) and treatment (39 cases) groups. Patients in the control group were im injection administered with Elcatonin Injection, 1 mL/time, once weekly. Patients in the treatment group were po administered with Jinwu Gutong Capsules on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the VAS and ODI scores, and bone metabolism indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.05% and 97.44%, respectively, and there were differences between two groups (P < 0.05). After treatment, the VAS and ODI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, serum SOST and BGP levels in two groups were significantly increased, but β-CTX, TRACP, and N-MID levels were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these bone metabolism indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Jinwu Gutong Capsules combined with calcitonin has clinical curative effect in treatment of osteoporosis, can effectively improve the clinical symptoms and serum bone metabolism markers, which has a certain clinical application value.